Press release
Investigation announced for Long-Term Investors in shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR) over potential Wrongdoing
An investigation on behalf of current long term investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares.
Investors who are current long term investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: CAPR stocks follows a lawsuit filed against Capricor Therapeutics, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: CAPR stocks, concerns whether certain Capricor Therapeutics, Inc. directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Southern District of California the plaintiff alleges that, the defendants provided investors with material information concerning Capricor's lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy. Defendants' statements included, among other things, Capricor's ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration, and that the Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel, causing Plaintiff and other shareholders to purchase Capricor's securities at artificially inflated prices.
Those who purchased shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR) over potential Wrongdoing here
News-ID: 4188762 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit Alert: Investors who lost money with shares of Molina Healthcare, Inc. ( …
An investor, who purchased shares of Molina Healthcare, Inc. (NYSE: MOH), filed a lawsuit over alleged violations of Federal Securities Laws by Molina Healthcare, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Molina Healthcare, Inc. (NYSE: MOH) have certain options and for certain investors are short and strict deadlines running. Deadline: December 02, 2025. NYSE: MOH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
CTO Realty Growth, Inc. (NYSE: CTO) Long Term Investor Alert: Investigation of p …
An investigation on behalf of current long-term investors in shares of CTO Realty Growth, Inc. (NYSE: CTO) concerning potential breaches of fiduciary duties by certain directors and officers of CTO Realty Growth, Inc. was announced.
Investors who are current long term investors in CTO Realty Growth, Inc. (NYSE: CTO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a…
Lawsuit filed for Investors who lost money with shares of Marex Group plc (NASDA …
An investor, who purchased shares of Marex Group plc (NASDAQ: MRX), filed a lawsuit in the U.S. District Court for the Southern District of New York over alleged violations of Federal Securities Laws by Marex Group plc in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of Marex Group plc (NASDAQ: MRX) between May 16, 2024 and August 5, 2025, have certain options…
LifeMD, Inc. (NASDAQ: LFMD) Investor Alert: Deadline in Lawsuit on October 27, 2 …
A deadline is coming up on October 27, 2025 in the lawsuit filed for certain investors of LifeMD, Inc. (NASDAQ: LFMD) over alleged securities laws violations by LifeMD, Inc.
Investors who purchased shares of LifeMD, Inc. (NASDAQ: LFMD) have certain options and there are strict and short deadlines running. Deadline: October 27, 2025. LifeMD, Inc. (NASDAQ: LFMD) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Capricor
Dilated Cardiomyopathy Pipeline Analysis, 2024 Updates | Latest FDA, EMA, and PM …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Dilated Cardiomyopathy pipeline constitutes 10+ key companies continuously working towards developing 10+ Dilated Cardiomyopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Dilated Cardiomyopathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
Exosome Technologies Market Report- Key companies: Capricor Therapeutics Inc, Ev …
Global Exosome Technologies Market research study offers a complete analysis of critical aspects of the current market situation including market competition, segmentation, geographical progress, and dynamic factors during the forecast period. The Exosome Technologies Market report offers insights into the potential size, volume, production, growth, revenue, and other estimations for the global as well as regional markets. This report also explains the Exosome Technologies Market share by company, investment strategies,…
Exosome Therapeutic Market In-depth Analysis by Statistics & Outlook 2027 |ReNeu …
The Global Exosome Therapeutic Market report provides information about the industry, including valuable Analysis and Detailed study. This research study explores the Global Exosome Therapeutic Market in detail such as industry chain structures, raw material suppliers, with manufacturing. The Exosome Therapeutic market examines the primary segments of the market. This intelligent study provides historical data from forecast from 2021 to 2027.It also provides the details such as whether the customers…
Dilated Cardiomyopathy Market 2019 Analysis and Precise Outlook - Capricor Thera …
The report titled “Dilated Cardiomyopathy Market” has recently added by MarketInsightsReports to get a stronger and effective business outlook. It provides an in-depth analysis of different attributes of industries such as trends, policies, and clients operating in several regions. The qualitative and quantitative analysis techniques have been used by analysts to provide accurate and applicable data to the readers, business owners, and industry experts.
The global Dilated Cardiomyopathy market is valued…
2019 Global Exosome Technologies Market- Capricor, Codiak and Evox Therapeutics …
Researchmoz added Most up-to-date research on "Exosome Technologies: Recent Surge in R&D with Capricor, Codiak and Evox Therapeutics among Key Players" to its huge collection of research reports.
GBI Research’s latest report, Exosome Technologies: Recent Surge in R&D with Capricor, Codiak and Evox Therapeutics among Key Players, explores the application of exosome technologies within the pharmaceutical and healthcare industries. Exosomes are small cell-derived vesicles that are abundant in bodily fluids, including…
Global Intravenous-to-Subcutaneous Drug Market 2017 : Baxter, Britannia, Caprico …
Global Intravenous-to-Subcutaneous Drug Market 2016-2017
A market study based on the " Intravenous-to-Subcutaneous Drug Market " across the globe, recently added to the repository of Market Research, is titled ‘Global Intravenous-to-Subcutaneous Drug Market 2017’. The research report analyses the historical as well as present performance of the worldwide Intravenous-to-Subcutaneous Drug industry, and makes predictions on the future status of Intravenous-to-Subcutaneous Drug market on the basis of this analysis.
Get Free Sample Copy…
